Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study

The Lancet

Volumn 393, Issue 10179, 2019, Pages 1453-1464

  Carrat, Fabrice ^a,b   Fontaine, Hélène ^c   Dorival, Céline ^a   Simony, Mélanie ^e   Diallo, Alpha ^f   Hezode, Christophe ^g   De Ledinghen, Victor ^h   Larrey, Dominique ⁱ   Haour, Georges ^a   Bronowicki, Jean Pierre ^j   Zoulim, Fabien ^k   Asselah, Tarik ^l   Marcellin, Patrick ^l   Thabut, Dominique ^l   Leroy, Vincent ^m   Tran, Albert ⁿ   Habersetzer, François ^o   Samuel, Didier ^p   Guyader, Dominique ^q   Chazouilleres, Olivier ^b   Mathurin, Philippe ^r   Metivier, Sophie ^s   Alric, Laurent ^s,t   Riachi, Ghassan ^u   Gournay, Jérôme ^v   Abergel, Armand ^w   Cales, Paul ^x,y   Ganne, Nathalie ^z,aa   Loustaud Ratti, Véronique ^ab   D'Alteroche, Louis ^ac   Causse, Xavier ^ad   Geist, Claire ^ae   Minello, Anne ^af   Rosa, Isabelle ^ag   Gelu Simeon, Moana ^ah,ai   Portal, Isabelle ^aj   Raffi, François ^ak   Bourliere, Marc ^al   Pol, Stanislas ^c,d   more..

^a SORBONNE UNIVERSITÉ   (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c Unité d'Hépatologie ^*  (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e Unit for Basic and Clinical Research on Viral Hepatitis   (France)

^f ANRS   (Emerging Infectious Diseases])

^g UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^h HAUT LÉVÊQUE HOSPITAL   (France)

ⁱ HÔPITAL SAINT ELOI   (France)

^j CHU NANCY BRABOIS   (France)

^k CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^l INSERM   (France)

^m GRENOBLE UNIVERSITY HOSPITAL   (France)

ⁿ UNIVERSITY HOSPITAL OF NICE   (France)

^o UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^p HÔPITAL PAUL BROUSSE   (France)

^q RENNES UNIVERSITY HOSPITAL   (France)

^r UNIV LILLE   (France)

^s CHU PURPAN   (France)

^t UMR 152 IRD Universite Paul Sabatier   (France)

^u HÔPITAL CHARLES NICOLLE   (France)

^v NANTES UNIVERSITY HOSPITAL   (France)

^w UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^x ANGERS UNIVERSITY HOSPITAL   (France)

^y Bretagne Loire University   (France)

^z ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^aa UNIVERSITÉ PARIS 13   (France)

^ab UNIVERSITY OF LIMOGES   (France)

^ac SERVICE DE DERMATOLOGIE   (France)

^ad CENTRE HOSPITALIER RÉGIONAL D ORLÉANS   (France)

^ae CHR   (France)

^af DIJON UNIVERSITY HOSPITAL   (France)

^ag CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^ah UNIVERSITÉ DES ANTILLES   (France)

^ai UNIVERSITÉ DE RENNES 1   (France)

^aj AIX MARSEILLE UNIVERSITY   (France)

^ak HÔTEL DIEU   (France)

^al HÔPITAL SAINT JOSEPH   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT;

ADULT; AGE; AGED; ALCOHOL CONSUMPTION; ALL CAUSE MORTALITY; ARTICLE; BODY MASS; CANCER RISK; CHRONIC HEPATITIS C; CLINICAL OUTCOME; COHORT ANALYSIS; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DISEASE ASSOCIATION; DRUG EXPOSURE; END STAGE LIVER DISEASE; FEMALE; FOLLOW UP; FRANCE; GENDER; GENOTYPE; GEOGRAPHIC ORIGIN; HUMAN; HYPERTENSION; INCIDENCE; LIVER CELL CARCINOMA; LIVER FIBROSIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY RATE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PLATELET COUNT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTHROMBIN TIME; QUANTITATIVE ANALYSIS; RISK REDUCTION; SURVIVAL TIME; CLINICAL TRIAL; LIVER CIRRHOSIS; LIVER TUMOR; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME;

ADULT; AGED; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; FEMALE; FRANCE; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 85063694042     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(18)32111-1     Document Type: Article

References (30)

1. WHO. Global hepatitis report, 2017. https://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/, April, 2017. (Accessed 7 January 2019)
2. Fontaine, H, Chaix, M-L, Lagneau, J-L, Bréchot, C, Pol, S, Recovery from chronic hepatitis C in long-term responders to ribavirin plus interferon alfa. Lancet, 356, 2000, 41.
3. Pearlman, BL, Traub, N, Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more. Clin Infect Dis 52 (2011), 889–900.
4. US Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research. Chronic hepatitis C virus infection: developing direct-acting antiviral drugs for treatment—guidance for industry. https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm225333.pdf, November, 2017. (Accessed 7 January 2019)
5. European Medicines Agency, Committee for Medicinal Products for Human Use. Guideline on the clinical evaluation of direct acting antivirals for the treatment of chronic hepatitis. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2016/07/WC500209917.pdf, June 23, 2016. (Accessed 7 January 2019)
6. Cheung, MC, Walker, AJ, Hudson, BE, et al. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 65 (2016), 741–747.
7. Innes, H, McDonald, S, Hayes, P, et al. Mortality in hepatitis C patients who achieve a sustained viral response compared to the general population. J Hepatol 66 (2017), 19–27.
8. Kanwal, F, Kramer, J, Asch, SM, Chayanupatkul, M, Cao, Y, El-Serag, HB, Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. Gastroenterology 153 (2017), 996–1005.
9. Nahon, P, Bourcier, V, Layese, R, et al. Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications. Gastroenterology 152 (2017), 142–156.
10. Simmons, B, Saleem, J, Heath, K, Cooke, GS, Hill, A, Long-term treatment outcomes of patients infected with hepatitis C virus: a systematic review and meta-analysis of the survival benefit of achieving a sustained virological response. Clin Infect Dis 61 (2015), 730–740.
11. van der Meer, AJ, Feld, JJ, Hofer, H, et al. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. J Hepatol 66 (2017), 485–493.
12. van der Meer, AJ, Veldt, BJ, Feld, JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 308 (2012), 2584–2593.
13. Jakobsen, JC, Nielsen, EE, Feinberg, J, et al. Direct-acting antivirals for chronic hepatitis C. Cochrane Database Syst Rev, 6, 2017 CD012143.
14. Butt, AA, Yan, P, Simon, TG, Abou-Samra, AB, Effect of paritaprevir/ritonavir/ombitasvir/dasabuvir and ledipasvir/sofosbuvir regimens on survival compared with untreated hepatitis C virus-infected persons: results from ERCHIVES. Clin Infect Dis 65 (2017), 1006–1011.
15. Maan, R, Feld, JJ, Risk for hepatocellular carcinoma after hepatitis C virus antiviral therapy with direct-acting antivirals: case closed?. Gastroenterology 153 (2017), 890–892.
16. Waziry, R, Hajarizadeh, B, Grebely, J, et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression. J Hepatol 67 (2017), 1204–1212.
17. Pol, S, Bourliere, M, Lucier, S, et al. Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients. J Hepatol 66 (2017), 39–47.
18. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2016. J Hepatol 66 (2017), 153–194.
19. Croquet, V, Vuillemin, E, Ternisien, C, et al. Prothrombin index is an indirect marker of severe liver fibrosis. Eur J Gastroenterol Hepatol 14 (2002), 1133–1141.
20. Oberti, F, Valsesia, E, Pilette, C, et al. Noninvasive diagnosis of hepatic fibrosis or cirrhosis. Gastroenterology 113 (1997), 1609–1616.
21. Adams, LA, Bulsara, M, Rossi, E, et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 51 (2005), 1867–1873.
22. Bedossa, P, Poynard, T, An algorithm for the grading of activity in chronic hepatitis C. Hepatology 24 (1996), 289–293.
23. Garcia-Tsao, G, Friedman, S, Iredale, J, Pinzani, M, Now there are many (stages) where before there was one: in search of a pathophysiological classification of cirrhosis. Hepatology 51 (2010), 1445–1449.
24. Trinchet, JC, Bourcier, V, Chaffaut, C, et al. Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort). Hepatology 62 (2015), 737–750.
25. Simon, R, Makuch, RW, A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias. Stat Med 3 (1984), 35–44.
26. Austin, PC, Stuart, EA, Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med 34 (2015), 3661–3679.
27. Gran, JM, Roysland, K, Wolbers, M, et al. A sequential Cox approach for estimating the causal effect of treatment in the presence of time-dependent confounding applied to data from the Swiss HIV Cohort Study. Stat Med 29 (2010), 2757–2768.
28. Tada, T, Kumada, T, Toyoda, H, et al. Viral eradication reduces all-cause mortality in patients with chronic hepatitis C virus infection: a propensity score analysis. Liver Int 36 (2016), 817–826.
29. Romano, A, Angeli, P, Piovesan, S, et al. Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: a prospective population study. J Hepatol 69 (2018), 345–352.
30. Prenner, SB, VanWagner, LB, Flamm, SL, Salem, R, Lewandowski, RJ, Kulik, L, Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals. J Hepatol 66 (2017), 1173–1181.